Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.
Paul M RidkerBrendan M EverettAruna PradhanJean G MacFadyenDaniel H SolomonElaine ZaharrisVirak MamAhmed HasanYves RosenbergErin IturriagaMilan GuptaMichelle TsigoulisSubodh VermaMichael ClearfieldPeter LibbySamuel Z GoldhaberRoger SeagleCyril OforiMohammad SaklayenSamuel ButmanNarendra SinghMichel Le MayOlivier BertrandJames JohnstonNina P PaynterRobert J Glynnnull nullPublished in: The New England journal of medicine (2018)
Among patients with stable atherosclerosis, low-dose methotrexate did not reduce levels of interleukin-1β, interleukin-6, or C-reactive protein and did not result in fewer cardiovascular events than placebo. (Funded by the National Heart, Lung, and Blood Institute; CIRT ClinicalTrials.gov number, NCT01594333.).